EQS-News: Eckert & Ziegler Achieves Further Earnings Growth and Double-Digit Sales Growth in the Medical Segment

3^rd quarter of 2025:

• Sales of €75.3 million (previous year: €70.1 million)
• EBIT before special items of €15.4 million (previous year: €14.2 million)
• Net income of €8.5 million (previous year: €5.3 million)

First 9 months of 2025:

• Sales of €224.1 million (previous year: €215.5 million)
• EBIT before special items of €50.8 million (previous year: €46.7 million)
• Net income of €29.9 million (previous year: €23.4 million)

Forecast for 2025:

• Sales of approx. €320 million (confirmed)
• EBIT before special items of approx. €78 million (confirmed)

Berlin, 13 November 2025. Eckert & Ziegler SE (ISIN DE0005659700, TecDAX) increased sales in the first nine months of 2025 by 4% to €224.1 million compared to the same period last year. EBIT before special items from continuing operations (adjusted EBIT) rose by 9% to €50.8 million. Net profit (from continuing and discontinued operations) grew by 28% to €29.9 million, or €0.48 per share.

In the Medical segment, sales in the first nine months of the year amounted to €119.7 million, up around €15.2 million or 15% on the previous year's level. The business with pharmaceutical radioisotopes remains the most important source of revenue. Particularly noteworthy here are the developments in sales of generators, licensing, and contract manufacturing & development (CDMO).

The Isotope Products segment generated external sales of €104.4 million, down €6.6 million or approximately 6% compared to the first nine months of the previous year. Shifts between product groups toward lower-margin products have become apparent in comparison to the same period last year.

For the current fiscal year 2025, the Executive Board confirms its profit forecast published on March 27, 2025, with sales of approx. €320 million and an adjusted EBIT of approx. €78 million.

The complete quarterly report can be viewed here: https://www.ezag.com/Q32025en

About Eckert & Ziegler.
Eckert & Ziegler SE, with more than 1.000 employees, is a leading specialist for isotope-related components in nuclear medicine and radiation therapy. The company offers a broad range of services and products for the radiopharmaceutical industry, from early development work to contract manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700) are listed in the TecDax index of Deutsche Börse.
Contributing to saving lives.

Your contact:
Eckert & Ziegler SE, Karolin Riehle, Investor Relations
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Tel.: +49 (0) 30 / 94 10 84-138, karolin.riehle@ezag.de, www.ezag.com